UNLABELLED: We sought to evaluate the effects of antiretroviral therapy on skeletal metabolism in Chinese individuals with human immunodeficiency virus. Patients switched to tenofovir/lamivudine + lopinavir/ritonavir after treatment failure had an increase in bone resorption marker levels by nearly 60%, which is greater than the magnitude previously described in non-Chinese populations. INTRODUCTION: Few studies have evaluated the effects of antiretroviral therapy on skeletal metabolism in Asian populations infected with human immunodeficiency virus (HIV). METHODS: We performed a secondary analysis of bone turnover markers (BTM) at baseline and 2 years in stored plasma samples collected from 2/2009 to 1/2013 as part of a multi-center trial. Two groups were compared: (1) treatment-naïve patients initiated on zidovudine (AZT)/lamivudine (3TC) plus nevirapine (NVP) and (2) patients who failed first-line therapy and were switched to tenofovir (TDF)/3TC plus lopinavir/ritonavir (LPVr). Tests included the bone resorption marker, C-terminal cross-linking telopeptide of type-1 collagen (CTX), and the bone formation marker procollagen type 1 N-terminal propeptide (P1NP). RESULTS: In the TDF/3TC + LPVr group, samples were available from 59 patients at baseline and 56 patients at 2 years. Of these, 36 patients had samples available from both time points. In the AZT/3TC + NVP group, plasma samples were analyzed from 82 participants at baseline and of those, 61 had samples at 2 years. Median change over 2 years was greater in the TDF/3TC + LPVr group for both CTX (+0.24 ng/mL, interquartile ranges (IQR) 0.10-0.43 vs. +0.09 ng/mL, IQR -0.03 to 0.18, p = 0.001) and P1NP (+25.5 ng/mL, IQR 2.4-51.3 vs. +7.11 ng/mL, IQR -4.3 to 21.6, p = 0.012). Differences remained after adjusting for potential confounders in the multivariable analysis. CONCLUSIONS: Switching to TDF/3TC + LPVr after treatment failure resulted in greater increases in BTMs than initiation with AZT/3TC + NVP in Chinese patients with HIV. Following this change, bone resorption marker levels increased by nearly 60 %, which is greater than the 25-35% increase from baseline described previously in non-Chinese populations. Further studies are warranted to elucidate these findings.
UNLABELLED: We sought to evaluate the effects of antiretroviral therapy on skeletal metabolism in Chinese individuals with human immunodeficiency virus. Patients switched to tenofovir/lamivudine + lopinavir/ritonavir after treatment failure had an increase in bone resorption marker levels by nearly 60%, which is greater than the magnitude previously described in non-Chinese populations. INTRODUCTION: Few studies have evaluated the effects of antiretroviral therapy on skeletal metabolism in Asian populations infected with human immunodeficiency virus (HIV). METHODS: We performed a secondary analysis of bone turnover markers (BTM) at baseline and 2 years in stored plasma samples collected from 2/2009 to 1/2013 as part of a multi-center trial. Two groups were compared: (1) treatment-naïve patients initiated on zidovudine (AZT)/lamivudine (3TC) plus nevirapine (NVP) and (2) patients who failed first-line therapy and were switched to tenofovir (TDF)/3TC plus lopinavir/ritonavir (LPVr). Tests included the bone resorption marker, C-terminal cross-linking telopeptide of type-1 collagen (CTX), and the bone formation marker procollagen type 1 N-terminal propeptide (P1NP). RESULTS: In the TDF/3TC + LPVr group, samples were available from 59 patients at baseline and 56 patients at 2 years. Of these, 36 patients had samples available from both time points. In the AZT/3TC + NVP group, plasma samples were analyzed from 82 participants at baseline and of those, 61 had samples at 2 years. Median change over 2 years was greater in the TDF/3TC + LPVr group for both CTX (+0.24 ng/mL, interquartile ranges (IQR) 0.10-0.43 vs. +0.09 ng/mL, IQR -0.03 to 0.18, p = 0.001) and P1NP (+25.5 ng/mL, IQR 2.4-51.3 vs. +7.11 ng/mL, IQR -4.3 to 21.6, p = 0.012). Differences remained after adjusting for potential confounders in the multivariable analysis. CONCLUSIONS: Switching to TDF/3TC + LPVr after treatment failure resulted in greater increases in BTMs than initiation with AZT/3TC + NVP in Chinese patients with HIV. Following this change, bone resorption marker levels increased by nearly 60 %, which is greater than the 25-35% increase from baseline described previously in non-Chinese populations. Further studies are warranted to elucidate these findings.
Authors: Aoife G Cotter; Saskia M E Vrouenraets; Jennifer J Brady; Ferdinand W Wit; Christoph A Fux; Hansjakob Furrer; Kees Brinkman; Caroline A Sabin; Peter Reiss; Patrick W G Mallon Journal: J Clin Endocrinol Metab Date: 2013-02-22 Impact factor: 5.958
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240
Authors: Birgit Grund; Grace Peng; Cynthia L Gibert; Jennifer F Hoy; Rachel L Isaksson; Judith C Shlay; Esteban Martinez; Peter Reiss; Fehmida Visnegarwala; Andrew D Carr Journal: AIDS Date: 2009-07-31 Impact factor: 4.177
Authors: P Rivas; M Górgolas; R García-Delgado; M Díaz-Curiel; A Goyenechea; M L Fernández-Guerrero Journal: HIV Med Date: 2007-12-18 Impact factor: 3.180
Authors: Carolien J P Van Den Bout-Van Den Beukel; Lydia Fievez; Meta Michels; Fred C G J Sweep; Ad R M M Hermus; Marjolein E W Bosch; David M Burger; Bert Bravenboer; Peter P Koopmans; André J A M Van Der Ven Journal: AIDS Res Hum Retroviruses Date: 2008-11 Impact factor: 2.205
Authors: Evelyn Hsieh; Liana Fraenkel; Yang Han; Weibo Xia; Karl L Insogna; Michael T Yin; Ting Zhu; Xinqi Cheng; Taisheng Li Journal: AIDS Date: 2016-07-31 Impact factor: 4.177
Authors: Julie A Womack; Terrence E Murphy; Christine Ramsey; Harini Bathulapalli; Linda Leo-Summers; Alexandria C Smith; Jonathan Bates; Samah Jarad; Thomas M Gill; Evelyn Hsieh; Maria C Rodriguez-Barradas; Phyllis C Tien; Michael T Yin; Cynthia Brandt; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2021-10-01 Impact factor: 3.771
Authors: Kate Braithwaite; Tristan D McPherson; Yanhan Shen; Stephen Arpadi; Stephanie Shiau; Gillian Sorour; Karl-Günter Technau; Michael T Yin Journal: South Afr J HIV Med Date: 2021-08-05 Impact factor: 2.744